Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene

Trial Profile

Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs GS 010 (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Registrational; Therapeutic Use
  • Acronyms REVERSE
  • Sponsors GenSight Biologics
  • Most Recent Events

    • 14 Jun 2017 Topline results at 48 weeks from this study are expected in the third quarter of 2018, according to a GenSight Biologics media release.
    • 21 Feb 2017 Topline results from this trial at 48 weeks are expected at the end of Q1 2018, according to a GenSight Biologics media release.
    • 21 Feb 2017 Status changed from recruiting to active, no longer recruiting, according to a GenSight Biologics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top